Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal.

Abstract

WHAT IS KNOWN AND OBJECTIVE:

Somatostatin analogues (SSAs) have been used for the treatment of acromegaly for several decades. However, a unified conclusion on the duration of SSAs therapy or the possibility of medication withdrawal is still missing. We aimed to report a case of acromegaly cured by pasireotide long-acting release (PAS-LAR) and provide some information on the withdrawal of SSAs after stable regression in acromegalic patients.

CASE SUMMARY:

A 55-year-old male patient, who was diagnosed with acromegaly and refused surgery and received PAS-LAR as initial treatment, had maintained stability for ten years under the regular treatment with PAS-LAR. The pituitary microadenoma was also decreased during the treatment. After the PAS-LAR discontinuation for 21 months, no evidence of biochemical or clinical recurrence was found in this patient.

WHAT IS NEW AND CONCLUSION:

The use of PAS-LAR in a subset of naive-treatment patients is promising to induce long-term regression. A subgroup of patients with mild and well-controlled acromegaly might hope for perpetual remission after the withdrawal of medication.

• Authors: Na Yu, Linjie Wang, Hongbo Yang, Hui Pan, Lian Duan, Huijuan Zhu
• Journal: Journal of clinical pharmacy and therapeutics (J Clin Pharm Ther) Vol. 47 Issue 6 Pg. 835-840 (Jun 2022) ISSN: 1365-2710 [Electronic] England
• PMID: 35167717 (Publication Type: Case Reports)
• Copyright: © 2022 John Wiley & Sons Ltd.

Chemical References

• Human Growth Hormone
• Somatostatin
• Insulin-Like Growth Factor I
• pasireotide
• Octreotide

Topics

• Acromegaly (drug therapy)
• Adenoma (chemically induced, complications, drug therapy)
• Growth Hormone-Secreting Pituitary Adenoma (chemically induced, complications, drug therapy)
• Human Growth Hormone (therapeutic use)
• Humans
• Insulin-Like Growth Factor I
• Male
• Middle Aged
• Octreotide
• Somatostatin (analogs & derivatives, therapeutic use)
• Treatment Outcome